Could a simple pill boost CAR T-Cell staying power against blood cancers?
NCT ID NCT05044039
First seen Dec 16, 2025 · Last updated May 23, 2026 · Updated 24 times
Summary
This early-phase study tests whether adding the drug duvelisib after CAR T-cell therapy can help the immune cells survive longer and fight non-Hodgkin lymphoma or acute lymphocytic leukemia more effectively. About 42 adults who are eligible for approved CAR T-cell treatments will receive duvelisib to see if it reduces side effects like cytokine release syndrome and improves cancer control. The main goal is to check safety and find the best dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.